PDCD1 and neoplasm: Monoclonal antibodies disrupt the interactions between PD‐1 and PD‐L1, increase T cell toxicity, restore the immune system's ability to monitor and eliminate tumors, and inhibit CD8+ T cell transformation to Treg cells.[64] Recent research has established a correlation between the efficacy of PI and the presence of CD8+ cells that have infiltrated the tumor.[65] Treg cells, a subset of CD4+ T cells that express Foxp3, have been demonstrated to suppress the ability of the immune system to produce an immune response against tumors and promote tumor immune evasion.